Xylem (XYL) Stock Could Still Be A Bargain Despite A 23% Slide
Xylem stock has fallen sharply over the past year, yet a fresh intrinsic value estimate points to a meaningful discount to what the market is currently pricing in. The Discounted Cash Flow (DCF) work suggests the stock may be trading below its estimated worth while traditional earnings multiples look closer to fair.
- Xylem shares are down 23.5% over the past year, which raises the question of whether the recent slide has pushed the stock below its underlying value.
- The valuation outlook can benefit if Xylem converts revenue into stable free cash flow. However, any sustained pressure on margins would make that cash flow less reliable and weaken the case for upside.
- The broader checks lean cheap, with Xylem scoring 6 out of 6 on value tests, even though market based multiples look roughly in line with peers.
The issue now is whether the market is correctly pricing Xylem or whether the current share price still leaves a margin between trading value and intrinsic value.
Compare Xylem's recent slide with other potential value setups by scanning 47 high quality undervalued stocks that currently screen well on both cash flow and balance sheet strength.
Does Xylem Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) method values Xylem by projecting future cash that could flow to shareholders and discounting it back to today. For Xylem, the model uses latest twelve month free cash flow of about $940.2 million and assumes that this cash generation grows over time rather than shrinking.
On these inputs, the DCF output points to an estimated intrinsic value of about $160 per share. That sits well above the current market price, which implies a discount of roughly 33.9% to the model’s fair value estimate. The projection path is relatively steady rather than explosive, which suggests the gap between price and estimated value is more about the market’s caution than about highly aggressive growth assumptions.
On this DCF view, Xylem stock currently screens as undervalued relative to the cash flows analysts expect it to produce.
Our Discounted Cash Flow (DCF) analysis suggests Xylem is undervalued by 33.9%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
Where Does Xylem Sit on Earnings?
The P/E multiple works well for Xylem because earnings are a key focus for investors comparing industrial stocks in the same Machinery industry. Xylem currently trades at about 24.2x earnings, which is slightly below the Machinery industry average of roughly 25.4x and also below the peer group average of about 28.8x.
A tailored fair P/E for Xylem is estimated at around 25.2x, which reflects its sector, size and risk profile rather than just a broad industry mean. The current 24.2x level is very close to that fair marker, which suggests the market is not applying a major premium or discount for the earnings that Xylem generates. This aligns with the view that much of the current discussion focuses on the cash flow outlook rather than on a clear mispricing based on simple earnings multiples.
On the P/E measure, Xylem stock appears roughly fairly valued with no strong indication of either cheapness or expensiveness.
See what the numbers say about this price — find out in our valuation breakdown.
The Xylem Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Xylem valuation gap leaves off and explain what would need to happen to Xylem's growth, margins and earnings for the stock to be worth materially more or less than today's price on the Community page. Rather than focusing on a single P/E or DCF output, each narrative lays out the assumptions that sit behind its fair value so you can track those against actual results over time.
One of the top community narratives on Xylem: 31% undervalued
"Bullish analysts see Xylem as a direct beneficiary of rising AI related data center water needs, arguing that water is an underappreciated constraint on AI buildouts…"
Read one of the top narratives on Xylem
Do you think there's more to the story for Xylem? Head over to our Community to see what others are saying!
The Bottom Line
For Xylem, the Discounted Cash Flow (DCF) work points to an intrinsic value that sits well above the current share price, while the P/E view looks close to what peers trade on. That mix suggests the opportunity hinges less on a clear multiple mispricing and more on whether the company can turn its revenue into reliable free cash flow over time. Broader valuation checks look encouraging, so the key debate from here is whether margins and cash generation prove solid enough for the intrinsic value case to hold rather than the current price reflecting a fair level of caution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com